BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 8777174)

  • 1. Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma.
    André T; Lotz JP; Bouleuc C; Azzouzi K; Houry S; Hannoun L; See J; Esteso A; Avenin D; Izrael V
    Ann Oncol; 1996 Feb; 7(2):173-8. PubMed ID: 8777174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
    Choi CW; Choi IK; Seo JH; Kim BS; Kim JS; Kim CD; Um SH; Kim JS; Kim YH
    Am J Clin Oncol; 2000 Aug; 23(4):425-8. PubMed ID: 10955877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Araneo M; Bruckner HW; Grossbard ML; Frager D; Homel P; Marino J; DeGregorio P; Mortazabi F; Firoozi K; Jindal K; Kozuch P
    Cancer Invest; 2003; 21(4):489-96. PubMed ID: 14533437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of 5-fluorouracil, leucovorin and cisplatin in advanced pancreatic cancer.
    Huguier M; Barrier A; Valinas R; Flahault A; Adloff M; Pezet D; Jaeck D; Millat B;
    Hepatogastroenterology; 2001; 48(39):875-8. PubMed ID: 11462946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
    Kornek GV; Schratter-Sehn A; Marczell A; Depisch D; Karner J; Krauss G; Haider K; Kwasny W; Locker G; Scheithauer W
    Br J Cancer; 2000 Jan; 82(1):98-103. PubMed ID: 10638974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A weekly 24-h infusion of high-dose 5-fluorouracil (5-FU)+leucovorin and bi-weekly cisplatin (CDDP) was active and well tolerated in patients with non-colon digestive carcinomas.
    Caroli-Bosc FX; Van Laethem JL; Michel P; Gay F; Hendlisz A; Forget F; Bleiberg H
    Eur J Cancer; 2001 Oct; 37(15):1828-32. PubMed ID: 11576835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer].
    Taïeb J; Lecomte T; Ezenfis J; Artru P; Mitry E; Boige V; Clavero-Fabri MC; Vaillant JN; Rougier P; Ducreux M
    Gastroenterol Clin Biol; 2002; 26(6-7):605-9. PubMed ID: 12193860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin.
    Sporn JR; Buzaid AC; Slater D; Cohen N; Greenberg BR
    Am J Clin Oncol; 1997 Feb; 20(1):81-3. PubMed ID: 9020295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and dipyridamole.
    Todd KE; Gloor B; Lane JS; Isacoff WH; Reber HA
    J Gastrointest Surg; 1998; 2(2):159-66. PubMed ID: 9834413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Chen LT; Liu TW; Wu CW; Chung TR; Shiah HS; Jan CM; Liu JM; Whang-Peng J; Chang JY
    Oncology; 2002; 63(3):239-47. PubMed ID: 12381903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.
    Ducreux M; Rougier P; Pignon JP; Douillard JY; Seitz JF; Bugat R; Bosset JF; Merouche Y; Raoul JL; Ychou M; Adenis A; Berthault-Cvitkovic F; Luboinski M;
    Ann Oncol; 2002 Aug; 13(8):1185-91. PubMed ID: 12181240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elimination of dose limiting toxicities of cisplatin, 5-fluorouracil, and leucovorin using a weekly 24-hour infusion schedule for the treatment of patients with nasopharyngeal carcinoma.
    Chi KH; Chan WK; Shu CH; Law CK; Chen SY; Yen SH; Chen KY
    Cancer; 1995 Dec; 76(11):2186-92. PubMed ID: 8635020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
    Nicolson M; Webb A; Cunningham D; Norman A; O'Brien M; Hill A; Hickish T
    Ann Oncol; 1995 Oct; 6(8):801-4. PubMed ID: 8589018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
    Louvet C; André T; Hammel P; Selle F; Landi B; Cattan S; Fonck M; Flesch M; Colin P; Balosso J; Ruszniewski P; de Gramont A
    Ann Oncol; 2001 May; 12(5):675-9. PubMed ID: 11432627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
    Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
    Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Goodwin JW; Balcerzak SP; Samlowski WE; Lenz HJ; Macdonald JS
    Invest New Drugs; 2004 Aug; 22(3):335-41. PubMed ID: 15122082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
    Oman M; Lundqvist S; Gustavsson B; Hafström LO; Naredi P
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):603-9. PubMed ID: 16047145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.